HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BASF restructures

This article was originally published in The Rose Sheet

Executive Summary

In effort to prepare for the integration of Cognis, German chemical firm BASF is downscaling its Care Chemicals division so that it comprises only personal care, hygiene, home care and industrial formulator categories, firm reports July 29. Effective Aug. 1, nutrition ingredients, aroma chemicals and pharma ingredients, previously under Care Chemicals, will make up the new Nutrition & Health division. Both divisions will continue to fall under the Performance Products segment. Gabriel Tanbourgi, president of the original Care Chemicals division, will continue to lead the unit. Walter Dissinger, currently VP, Crop Protection, Latin America, will be president of the new division. BASF acquired Cognis June 23 for $3.8 bil., making it the global leader in personal-care ingredients (1"The Rose Sheet" June 28, 2010)

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel